Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focusing on mRNA cell therapy for autoimmune diseases, has announced its participation in two upcoming investor conferences in September 2024:

1. H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 2:30 p.m. ET in New York, NY

2. Cantor Global Healthcare Conference on September 17 at 9:45 a.m. ET in New York, NY

The company's management will participate in fireside chats at both events. Live webcasts of these discussions will be available on the Events section of Cartesian Therapeutics' website, with archived replays accessible for a time.

GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

• A fireside chat at the H.C. Wainwright 26^th Annual Global Investment Conference at 2:30 p.m. ET on Monday, September 9, 2024 in New York, NY
• A fireside chat at the Cantor Global Healthcare Conference at 9:45 a.m. ET on Tuesday, September 17, 2024 in New York, NY

A live webcast of the fireside chats are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information:
Investor Relations:
Argot Partners
cartesian@argotpartners.com

Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

When is Cartesian Therapeutics (RNAC) participating in the H.C. Wainwright Global Investment Conference?

Cartesian Therapeutics (RNAC) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 2:30 p.m. ET in New York, NY.

What time is Cartesian Therapeutics' (RNAC) fireside chat at the Cantor Global Healthcare Conference?

Cartesian Therapeutics' (RNAC) fireside chat at the Cantor Global Healthcare Conference is scheduled for Tuesday, September 17, 2024, at 9:45 a.m. ET in New York, NY.

Where can investors access the webcasts of Cartesian Therapeutics' (RNAC) investor conference presentations?

Investors can access live webcasts of Cartesian Therapeutics' (RNAC) investor conference presentations in the Events section of the company's website at www.cartesiantherapeutics.com.

What is the main focus of Cartesian Therapeutics (RNAC) as a biotechnology company?

Cartesian Therapeutics (RNAC) is a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases.